BioAge Labs has secured $115.0 million in new funding from investors. The clinical-stage biotechnology company is dedicated to leveraging the biology of human aging to discover and develop novel targets and therapies for metabolic diseases. This significant capital raise underscores investor confidence in BioAge's unique approach and its potential to address age-related health challenges.
The company's proprietary platform is built upon an extensive dataset, encompassing over 65 million molecular measurements spanning more than 45 years of human aging. This platform provides deep biological insights, enabling the identification of druggable mechanisms for various age-related conditions. The newly acquired funds will be instrumental in advancing BioAge's pipeline and expanding its research capabilities.
A key focus for the company is its lead program, azelaprag, a potential first-in-class oral APJ agonist. Azelaprag is slated to enter Phase 2 trials, where it will be evaluated in combination with tirzepatide for the treatment of obesity in older adults. This program aims to amplify weight loss and improve body composition for patients undergoing obesity therapy with incretin drugs. The funding will directly support the progression of azelaprag through these crucial clinical stages.
Beyond its lead candidate, BioAge Labs also maintains a portfolio of preclinical programs. These initiatives target key pathways in metabolic aging, drawing on novel insights derived from its discovery platform built on human longevity data. The capital infusion will enable the company to accelerate these preclinical efforts, further validating its platform.
With this substantial investment, BioAge Labs is well-positioned to accelerate its mission of translating the biology of aging into transformative therapies. The company plans to use the funds for continued growth initiatives, advancing its clinical pipeline, and expanding its research into age-related metabolic diseases, ultimately aiming to improve health outcomes for older adults.
